IP Library › Granted Patent US 12668640

Granted Patent B2

US 12668640 · App. 18/198,937 · Granted Jun 30, 2026

Anti-CD30 antibody and chimeric antigen receptor comprising thereof

Inventors: Jong-Seo Lee (Gyeonggi-do, KR); Jong-Hoon Kim (Gyeonggi-Do, KR); Ki Hyun Kim (Seoul, KR); Hyun-Jong Lee (Incheon, KR); Marco Ruella (Ardmore, PA); Puneeth Guruprasad (Philadelphia, PA)

Assignees: ABCLON INC.; The Trustees of the University of Pennsylvania

C07K16/2878 A61K40/31 C07K14/7051 C07K14/70517 C07K14/70578 A61K2039/505 A61K2239/13 A61K2239/21 A61K2239/22 C07K2317/622 C07K2317/73 C07K2317/92 C07K2319/02 C07K2319/03 C07K2319/33

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 12668640
App. No.: 18/198,937
Granted: Jun 30, 2026
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Disclosed herein are a novel antibody and an antigen binding fragment thereof that targets CD30 to treat cancer, a chimeric antigen receptor, and a use thereof. The antibody, which binds specifically to CD30 that is highly expressed in cancer cells (specifically blood cancer), is very low in sequence homology with the CDR sequences of conventional CD30 targeting antibodies and thus has a unique sequence. Cells that express the chimeric antigen receptor including the anti-CD30 antibody or the antigen binding fragment responds to CD30-expressing positive cells to induce immune cell activity, thus finding advantageous applications as a CAR-immune cell product.

Claims (89)

1 . An anti-CD30 antibody or an antigen binding fragment thereof, comprising an immunoglobulin heavy-chain variable region domain and an immunoglobulin light-chain variable region domain, wherein:

i) the heavy-chain variable region domain comprises HCDR1, HCDR2, and HCDR3, wherein the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequence of SEQ ID NO: 1, 2, and 3, respectively; and the light-chain variable region domain comprises LCDR1, LCDR2, and LCDR3, wherein the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 4, 5, and 6, respectively;

ii) the heavy-chain variable region domain comprises HCDR1, HCDR2, and HCDR3, wherein the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequence of SEQ ID NO: 21, 22, and 23, respectively; and the light-chain variable region domain comprises LCDR1, LCDR2, and LCDR3, wherein the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 24, 25, and 26, respectively;

iii) the heavy-chain variable region domain comprises HCDR1, HCDR2, and HCDR3, wherein the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequence of SEQ ID NO: 41, 42, and 43, respectively; and the light-chain variable region domain comprises LCDR1, LCDR2, and LCDR3, wherein the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 44, 45, and 46, respectively;

iv) the heavy-chain variable region domain comprises HCDR1, HCDR2, and HCDR3, wherein the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequence of SEQ ID NO: 61, 62, and 63, respectively; and the light-chain variable region domain comprises LCDR1, LCDR2, and LCDR3, wherein the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 64, 65, and 66, respectively;

v) the heavy-chain variable region domain comprises HCDR1, HCDR2, and HCDR3, wherein the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequence of SEQ ID NO: 81, 82, and 83, respectively; and the light-chain variable region domain comprises LCDR1, LCDR2, and LCDR3, wherein the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 84, 85, and 86, respectively;

vi) the heavy-chain variable region domain comprises HCDR1, HCDR2, and HCDR3, wherein the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequence of SEQ ID NO: 101, 102, and 103, respectively; and the light-chain variable region domain comprises LCDR1, LCDR2, and LCDR3, wherein the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 104, 105, and 106, respectively;

vii) the heavy-chain variable region domain comprises HCDR1, HCDR2, and HCDR3, wherein the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequence of SEQ ID NO: 121, 122, and 123, respectively; and the light-chain variable region domain comprises LCDR1, LCDR2, and LCDR3, wherein the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 124, 125, and 126, respectively;

viii) the heavy-chain variable region domain comprises HCDR1, HCDR2, and HCDR3, wherein the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequence of SEQ ID NO: 141, 142, and 143, respectively; and the light-chain variable region domain comprises LCDR1, LCDR2, and LCDR3, wherein the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 144, 145, and 146, respectively;

ix) the heavy-chain variable region domain comprises HCDR1, HCDR2, and HCDR3, wherein the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequence of SEQ ID NO: 161, 162, and 163, respectively; and the light-chain variable region domain comprises LCDR1, LCDR2, and LCDR3, wherein the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 164, 165, and 166, respectively;

x) the heavy-chain variable region domain comprises HCDR1, HCDR2, and HCDR3, wherein the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequence of SEQ ID NO: 181, 182, and 183, respectively; and the light-chain variable region domain comprises LCDR1, LCDR2, and LCDR3, wherein the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 184, 185, and 186, respectively; or

xi) the heavy-chain variable region domain comprises HCDR1, HCDR2, and HCDR3, wherein the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequence of SEQ ID NO: 201, 202, and 203, respectively; and the light-chain variable region domain comprises LCDR1, LCDR2, and LCDR3, wherein the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 204, 205, and 206, respectively.

2 . The anti-CD30 antibody or the antigen binding fragment thereof according to claim 1 , wherein the anti-CD30 antibody or the antigen binding fragment thereof comprises a heavy chain variable region domain and a light chain variable region domain, wherein:

i) the heavy-chain variable region domain comprises the amino acid sequence of SEQ ID NO: 7; and the light-chain variable region domain comprises the amino acid sequence of SEQ ID NO: 8;

ii) the heavy-chain variable region domain comprises the amino acid sequence of SEQ ID NO: 27; and the light-chain variable region domain comprises the amino acid sequence of SEQ ID NO: 28;

iii) the heavy-chain variable region domain comprises the amino acid sequence of SEQ ID NO: 47; and the light-chain variable region domain comprises the amino acid sequence of SEQ ID NO: 48;

iv) the heavy-chain variable region domain comprises the amino acid sequence of SEQ ID NO: 67; and the light-chain variable region domain comprises the amino acid sequence of SEQ ID NO: 68;

v) the heavy-chain variable region domain comprises the amino acid sequence of SEQ ID NO: 87; and the light-chain variable region domain comprises the amino acid sequence of SEQ ID NO: 88;

vi) the heavy-chain variable region domain comprises the amino acid sequence of SEQ ID NO: 107; and the light-chain variable region domain comprises the amino acid sequence of SEQ ID NO: 108;

vii) the heavy-chain variable region domain comprises the amino acid sequence of SEQ ID NO: 127; and the light-chain variable region domain comprises the amino acid sequence of SEQ ID NO: 128;

viii) the heavy-chain variable region domain comprises the amino acid sequence of SEQ ID NO: 147; and the light-chain variable region domain comprises the amino acid sequence of SEQ ID NO: 148;

ix) the heavy-chain variable region domain comprises the amino acid sequence of SEQ ID NO: 167; and the light-chain variable region domain comprises the amino acid sequence of SEQ ID NO: 168;

x) the heavy-chain variable region domain comprises the amino acid sequence of SEQ ID NO: 187; and the light-chain variable region domain comprises the amino acid sequence of SEQ ID NO: 188; or

xi) the heavy-chain variable region domain comprises the amino acid sequence of SEQ ID NO: 207; and the light-chain variable region domain comprises the amino acid sequence of SEQ ID NO: 208.

3 . The anti-CD30 antibody or the antigen binding fragment thereof according to claim 1 , wherein the anti-CD30 antibody or the antigen binding fragment thereof comprises an scFv, wherein the scFv comprises an amino acid sequence selected from the group consisting of the amino acid sequence of SEQ ID NO: 9, the amino acid sequence of SEQ ID NO: 29, the amino acid sequence of SEQ ID NO: 49, the amino acid sequence of SEQ ID NO: 69, the amino acid sequence of SEQ ID NO: 89, the amino acid sequence of SEQ ID NO: 109, the amino acid sequence of SEQ ID NO: 129, the amino acid sequence of SEQ ID NO: 149, the amino acid sequence of SEQ ID NO: 169, the amino acid sequence of SEQ ID NO: 189, and the amino acid sequence of SEQ ID NO: 209.

4 . The anti-CD30 antibody or the antigen binding fragment thereof according to claim 1 , wherein the antigen binding fragment is a Fab, Fab′, F(ab′) 2 , Fv, scFv, or chemically linked F(ab′) 2 .

5 . A nucleic acid molecule encoding the anti-CD30 antibody or the antigen binding fragment thereof according to claim 1 .

6 . The nucleic acid molecule according to claim 5 , wherein the nucleic acid molecule comprises nucleotide sequences selected from the group consisting of:

i) the nucleotide sequence of SEQ ID NO: 11, the nucleotide sequence of SEQ ID NO: 12, the nucleotide sequence of SEQ ID NO: 13, the nucleotide sequence of SEQ ID NO: 14, the nucleotide sequence of SEQ ID NO: 15, and the nucleotide sequence of SEQ ID NO: 16, wherein the nucleotide sequence encodes HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, respectively;

ii) the nucleotide sequence of SEQ ID NO: 31, the nucleotide sequence of SEQ ID NO: 32, the nucleotide sequence of SEQ ID NO: 33, the nucleotide sequence of SEQ ID NO: 34, the nucleotide sequence of SEQ ID NO: 35, and the nucleotide sequence of SEQ ID NO: 36, wherein the nucleotide sequence encodes HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, respectively;

iii) the nucleotide sequence of SEQ ID NO: 51, the nucleotide sequence of SEQ ID NO: 52, the nucleotide sequence of SEQ ID NO: 53, the nucleotide sequence of SEQ ID NO: 54, the nucleotide sequence of SEQ ID NO: 55, and the nucleotide sequence of SEQ ID NO: 56, wherein the nucleotide sequence encodes HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, respectively;

iv) the nucleotide sequence of SEQ ID NO: 71, the nucleotide sequence of SEQ ID NO: 72, the nucleotide sequence of SEQ ID NO: 73, the nucleotide sequence of SEQ ID NO: 74, the nucleotide sequence of SEQ ID NO: 75, and the nucleotide sequence of SEQ ID NO: 76, wherein the nucleotide sequence encodes HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, respectively;

v) the nucleotide sequence of SEQ ID NO: 91, the nucleotide sequence of SEQ ID NO: 92, the nucleotide sequence of SEQ ID NO: 93, the nucleotide sequence of SEQ ID NO: 94, the nucleotide sequence of SEQ ID NO: 95, and the nucleotide sequence of SEQ ID NO: 96, wherein the nucleotide sequence encodes HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, respectively;

vi) the nucleotide sequence of SEQ ID NO: 111, the nucleotide sequence of SEQ ID NO: 112, the nucleotide sequence of SEQ ID NO: 113, the nucleotide sequence of SEQ ID NO: 114, the nucleotide sequence of SEQ ID NO: 115, and the nucleotide sequence of SEQ ID NO: 116, wherein the nucleotide sequence encodes HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, respectively;

vii) the nucleotide sequence of SEQ ID NO: 131, the nucleotide sequence of SEQ ID NO: 132, the nucleotide sequence of SEQ ID NO: 133, the nucleotide sequence of SEQ ID NO: 134, the nucleotide sequence of SEQ ID NO: 135, and the nucleotide sequence of SEQ ID NO: 136, wherein the nucleotide sequence encodes HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, respectively;

viii) the nucleotide sequence of SEQ ID NO: 151, the nucleotide sequence of SEQ ID NO: 152, the nucleotide sequence of SEQ ID NO: 153, the nucleotide sequence of SEQ ID NO: 154, the nucleotide sequence of SEQ ID NO: 155, and the nucleotide sequence of SEQ ID NO: 156, wherein the nucleotide sequence encodes HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, respectively;

ix) the nucleotide sequence of SEQ ID NO: 171, the nucleotide sequence of SEQ ID NO: 172, the nucleotide sequence of SEQ ID NO: 173, the nucleotide sequence of SEQ ID NO: 174, the nucleotide sequence of SEQ ID NO: 175, and the nucleotide sequence of SEQ ID NO: 176, wherein the nucleotide sequence encodes HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, respectively;

x) the nucleotide sequence of SEQ ID NO: 191, the nucleotide sequence of SEQ ID NO: 192, the nucleotide sequence of SEQ ID NO: 193, the nucleotide sequence of SEQ ID NO: 194, the nucleotide sequence of SEQ ID NO: 195, and the nucleotide sequence of SEQ ID NO: 196, wherein the nucleotide sequence encodes HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, respectively; and

xi) the nucleotide sequence of SEQ ID NO: 211, the nucleotide sequence of SEQ ID NO: 212, the nucleotide sequence of SEQ ID NO: 213, the nucleotide sequence of SEQ ID NO: 214, the nucleotide sequence of SEQ ID NO: 215, and the nucleotide sequence of SEQ ID NO: 216, wherein the nucleotide sequence encodes HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, respectively.

7 . The nucleic acid molecule according to claim 5 , wherein the nucleic acid molecule comprises nucleotide sequences selected from the group consisting of:

i) the nucleotide sequence of SEQ ID NO: 17 and the nucleotide sequence of SEQ ID NO: 18, wherein the nucleotide sequences encode the heavy chain variable domain and the light chain variable domain, respectively;

ii) the nucleotide sequence of SEQ ID NO: 37 and the nucleotide sequence of SEQ ID NO: 38, wherein the nucleotide sequences encode the heavy chain variable domain and the light chain variable domain, respectively;

iii) the nucleotide sequence of SEQ ID NO: 57 and the nucleotide sequence of SEQ ID NO: 58, wherein the nucleotide sequences encode the heavy chain variable domain and the light chain variable domain, respectively;

iv) the nucleotide sequence of SEQ ID NO: 77 and the nucleotide sequence of SEQ ID NO: 78, wherein the nucleotide sequences encode the heavy chain variable domain and the light chain variable domain, respectively;

v) the nucleotide sequence of SEQ ID NO: 97 and the nucleotide sequence of SEQ ID NO: 98, wherein the nucleotide sequences encode the heavy chain variable domain and the light chain variable domain, respectively;

vi) the nucleotide sequence of SEQ ID NO: 117 and the nucleotide sequence of SEQ ID NO: 118, wherein the nucleotide sequences encode the heavy chain variable domain and the light chain variable domain, respectively;

vii) the nucleotide sequence of SEQ ID NO: 137 and the nucleotide sequence of SEQ ID NO: 138, wherein the nucleotide sequences encode the heavy chain variable domain and the light chain variable domain, respectively;

viii) the nucleotide sequence of SEQ ID NO: 157 and the nucleotide sequence of SEQ ID NO: 158, wherein the nucleotide sequences encode the heavy chain variable domain and the light chain variable domain, respectively;

ix) the nucleotide sequence of SEQ ID NO: 177 and the nucleotide sequence of SEQ ID NO: 178, wherein the nucleotide sequences encode the heavy chain variable domain and the light chain variable domain, respectively;

x) the nucleotide sequence of SEQ ID NO: 197 and the nucleotide sequence of SEQ ID NO: 198, wherein the nucleotide sequences encode the heavy chain variable domain and the light chain variable domain, respectively; and

xi) the nucleotide sequence of SEQ ID NO: 217 and the nucleotide sequence of SEQ ID NO: 218, wherein the nucleotide sequences encode the heavy chain variable domain and the light chain variable domain, respectively.

8 . The nucleic acid molecule according to claim 5 , wherein the nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of the nucleotide sequence of SEQ ID NO: 19, the nucleotide sequence of SEQ ID NO: 39, the nucleotide sequence of SEQ ID NO: 59, the nucleotide sequence of SEQ ID NO: 79, the nucleotide sequence of SEQ ID NO: 99, the nucleotide sequence of SEQ ID NO: 119, the nucleotide sequence of SEQ ID NO: 139, the nucleotide sequence of SEQ ID NO: 159, the nucleotide sequence of SEQ ID NO: 179, the nucleotide sequence of SEQ ID NO: 199, and the nucleotide sequence of SEQ ID NO: 219, wherein the nucleotide sequence encodes an scFv.

9 . A CD30-specific chimeric antigen receptor, comprising:

an anti-CD30 antibody or an antigen binding fragment thereof;

a transmembrane domain; and

an intracellular signaling domain,

wherein the anti-CD30 antibody or the antigen binding fragment thereof comprises a heavy chain variable region domain and a light chain variable region domain, wherein:

10 . The CD30-specific chimeric antigen receptor of claim 9 , wherein the anti-CD30 antibody or the antigen binding fragment thereof comprises a heavy chain variable region domain and a light chain variable region domain, wherein: